Having failed to observe any changes in the preleukaemic cell populations that might account for the slower onset of tumour-associated morbidity, we decided to assess Eμ-myc lymphomas to ascertain whether reduced Mnt had increased the probability of malignant Myc-driven cells undergoing cell death in vivo or reduced their proliferation rate. The gene discussed is MYC; the disease is lymphoma.